ArticleLipids in health and disease2026
The effects of a body shape index and remnant cholesterol inflammatory index on incident cardiovascular diseases: insights from a nationwide cohort study.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhile a body shape index (ABSI) and remnant cholesterol inflammatory index (RCII) are established cardiovascular risk factors, their joint, interactive, and mediating effects with incident cardiovascular diseases (CVD) remain poorly characterized. This prospective investigation examined how ABSI and RCII might influence CVD incidence.
methodsThis prospective analysis leveraged nationally representative data from the China Health and Retirement Longitudinal Study (CHARLS), encompassing 7,780 participants aged ≥ 45 years without CVD at baseline. ABSI and RCII served as primary exposures. Incident CVD (heart diseases or stroke) were identified through guideline-based diagnosis or verified self-reports. Analyses were performed using SPSS software v.25.0 and R software v.4.4.4.
resultsOut of 7,780 individuals, 560 (25.48%) developed CVD. Compared to the first quartile of ABSI, the adjusted hazard ratios (HRs) for CVD in the second, third and fourth quartile were 1.26 [95% confidence interval (CI): 1.10–1.44], 1.15 [95% CI: 1.00-1.32], and 1.20 [95% CI: 1.04–1.38], respectively. High RCII group conferred a 1.19-fold higher risk [95% CI: 1.09–1.31] versus low RCII group. When participants were stratified into eight groups by ABSI quartiles and RCII quartiles, the second ABSI quartile with high RCII showed the highest HR of 1.43 [95% CI:1.20–1.72], while the fourth ABSI quartile with high RCII had the greatest absolute CVD incidence. The proportion of RCII’s mediating effects in the second, third, and fourth quartiles of ABSI was 5.00%, 12.84%, and 17.17%, respectively. Compared with traditional models, the area under curve of ABSI, RCII, and ABSI + RCII to predict incident CVD were 0.643, 0.644, and 0.645, respectively.
conclusionABSI and RCII demonstrate joint effects on CVD and serve as valuable tools for improving cardiovascular risk stratification among middle-aged and elderly Chinese population. RCII partially mediates the association between ABSI and CVD. Their combined use, particularly in identifying high-risk subgroups, supports the development of more targeted and efficient preventive strategies, which is crucial for alleviating the growing burden of CVD within aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.